Tenet Healthcare (THC) News Today

Tenet Healthcare Corporation (NYSE: THC) shares have been trading higher amid a flurry of analyst upgrades, price-target hikes and strong Q2 results. Investors are cheering new “buy” and “outperform” ratings from UBS, Raymond James and Guggenheim, a fresh 52-week high, raised 2025 guidance and bullish options activity. On the downside, Barclays trimmed its target slightly and concerns over potential Medicaid cuts linger.

• Positive Sentiment: UBS Group raised its price target on THC from $230 to $238 and reiterated a “buy” rating. UBS Group Forecasts Strong Price Appreciation for Tenet Healthcare (NYSE:THC) Stock
• Positive Sentiment: Raymond James Financial reaffirmed an “outperform” rating and lifted its target to $200 from $185. Tenet Healthcare (NYSE:THC) Given "Outperform" Rating at Raymond James Financial
• Positive Sentiment: Guggenheim raised its price objective to $188 (from $180) and maintained a “buy” stance. Tenet Healthcare (NYSE:THC) Price Target Raised to $188.00
• Positive Sentiment: Analysts boosted forecasts after upbeat Q2 results, highlighting better-than-expected earnings. These Analysts Boost Their Forecasts On Tenet Healthcare After Upbeat Q2 Results
• Positive Sentiment: American Banking News noted THC shares hit a 52-week high following strong Q2 earnings. Tenet Healthcare (NYSE:THC) Hits New 52-Week High on Better-Than-Expected Earnings
• Positive Sentiment: USPI segment added 8 ASCs as Tenet raised its 2025 guidance. ‘USPI continues to deliver’: Tenet adds 8 ASCs, raises 2025 guidance
• Positive Sentiment: Tenet raised its full-year 2025 guidance after Q2 and largely sidestepped policy headwinds. Tenet Raises 2025 Guidance After Q2 Earnings, Sidesteps Policy Concerns
• Positive Sentiment: Zacks noted bullish options market activity in THC shares suggests potential upside. Is the Options Market Predicting a Spike in Tenet Healthcare Stock?
• Positive Sentiment: Zacks highlighted THC among medical stocks poised to beat earnings using its Earnings ESP tool. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Barclays cut its price target slightly to $208 from $215 but kept an “overweight” rating. Benzinga
• Neutral Sentiment: Full Q2 2025 earnings call transcript published. Tenet Healthcare Corporation (THC) Q2 2025 Earnings Call Transcript
• Neutral Sentiment: Becker’s reviews how Tenet adapted to rising denial pressure in its revenue cycle. How Tenet adapted to growing denial pressure
• Neutral Sentiment: A retrospective on a $100 investment in Tenet five years ago. $100 Invested In Tenet Healthcare 5 Years Ago Would Be Worth This Much Today
• Neutral Sentiment: MSN previews HCA Healthcare’s Q2 as peer context ahead of earnings. HCA Healthcare (HCA) Reports Q2: Everything You Need To Know Ahead Of Earnings
• Negative Sentiment: Analysts caution that proposed Medicaid cuts could threaten Tenet’s growth beyond 2026 despite Q2 strength. Tenet Healthcare Continues To Win In Q2, But Medicaid Cuts May Threaten Growth Beyond 2026